Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast09 first-line HER2-positive metastatic breast cancer study
2023-505249-24-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised trial of trastuzumab deruxtecan, pertuzumab, trastuzumab, paclitaxel and docetaxel in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival by BICR. Planned start May 2021; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505249-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505249-24-00.